| Course | PA 512 CCM Hematology/Oncology |
|---|---|
| Week | 7 |
| Paper type | Tumor marker monitoring brief |
| Length | About 530 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | Master of Physician Assistant Studies (MPAS) |
| Updated | October 2026 |
Free sample paper for PA 512 Week 7
Tumor Marker Monitoring Brief: J.L.'s AFP Plateau After Orchiectomy, Its Fall Through Three Cycles of Chemotherapy and One Value From a Different Assay Set Aside
Student Name
Chamberlain University
PA 512: CCM Hematology/Oncology
Instructor Name
Month Day, Year
Tumor Marker Monitoring Brief: J.L.'s AFP Plateau After Orchiectomy, Its Fall Through Three Cycles of Chemotherapy and One Value From a Different Assay Set Aside
The Values
Table 1
AFP and hCG With Dates, Laboratory and Assay
| Date | AFP (ng/mL) | hCG (mIU/mL) | Laboratory and assay | Note |
|---|---|---|---|---|
| Feb 3 | 1,480 | 2,150 | Cancer center, Assay 1 | Before orchiectomy |
| Feb 14 | 690 | 62 | Cancer center, Assay 1 | Day 10 after surgery |
| Feb 21 | 640 | 14 | Cancer center, Assay 1 | Day 17 after surgery |
| Mar 2 | 655 | 9 | Cancer center, Assay 1 | Chemotherapy cycle 1 begins |
| Mar 9 | 495 | Not done | Urgent care, Assay 2 | Different assay; not in the run |
| Mar 23 | 210 | under 2 | Cancer center, Assay 1 | Cycle 2 begins |
| Apr 13 | 31 | under 2 | Cancer center, Assay 1 | Cycle 3 begins |
| May 4 | 7 | under 2 | Cancer center, Assay 1 | Reference: AFP under 9 |
Note. Note. Chemotherapy was bleomycin, etoposide and cisplatin, three cycles of 21 days.
One Assay Throughout
The Mar 9 value was measured at an urgent care center on a different platform. Different AFP assays can give different results on the same sample, so the value is listed but not used in the run. Every value used below comes from the cancer center's assay.
Movement Against Variation
The cancer center reports a between-run variation of about 6% for AFP at these levels. The change from 690 to 640 ng/mL between Feb 14 and Feb 21 is about 7%, barely beyond that variation. The change from 210 to 31 ng/mL during chemotherapy is far beyond it.
Pace, Where a Pace Is Given
AFP is cleared from the blood with a half-life of about five to seven days (Gilligan et al., 2010). If the Feb 14 value of 690 ng/mL had been falling only because the tumor was removed, it should have been about 260 to 345 ng/mL one week later. It was 640. The implied half-life over that week is more than two months, which is a plateau, not clearance. A plateau above normal after orchiectomy means AFP is still being produced, consistent with the disease in the para-aortic node seen on CT.
During chemotherapy, AFP fell from 210 to 31 ng/mL over 21 days, which works out to a half-life of about 7.6 days, close to the expected rate. hCG, with a half-life of about one and a half to three days, had already normalized before chemotherapy began. By May 4, AFP was in the normal range.
What the Run Is For
The run answers two questions: whether disease remained after surgery, and whether it is responding to treatment. The plateau answered the first, and the steady fall at the expected rate answers the second. A slower fall, or a rise, would have been the signal to act. The run does not say whether the node on CT contains living tumor, fibrosis or teratoma, which do not make AFP; that question is for imaging and, if needed, surgery.
References
Gilligan, T. D., Seidenfeld, J., Basch, E. M., Einhorn, L. H., Fancher, T., Smith, D. C., Stephenson, A. J., Vaughn, D. J., Cosby, R., & Hayes, D. F. (2010). American Society of Clinical Oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. Journal of Clinical Oncology, 28(20), 3388-3404. https://doi.org/10.1200/JCO.2009.26.4481
The Chamberlain PA 512 Week 7 instructions
Week seven asks for a brief, often a page or less, interpreting a series of tumor marker values. List the values first with a date for each and, where the case gives them, the assay and laboratory. Use one assay throughout and set aside values from another platform rather than mixing them into the run. Judge whether each movement is larger than the variation the measurement carries anyway. Where the marker has a known clearance rate, compare the observed pace with the expected one and show the calculation. Say what the run is being used for, such as detecting remaining disease or judging response, and what it cannot show. Cite a source for half-lives or other figures. Keep to the headings your section names, and do not turn the brief into a treatment plan.
Inside the PA 512 Week 7 example
A table lists eight dates from February 3 to May 4 with AFP, hCG, laboratory, assay and a note, including one March value from an urgent care center on a different platform, which is set aside. A section on variation compares the 7% change between February 14 and 21 with the assay's stated 6% variation, and the large fall during chemotherapy against it. The pace section uses an AFP half-life of five to seven days to show that the value should have fallen to roughly 260 to 345 ng/mL after a week and instead stayed at 640, an implied half-life of more than two months, meaning a plateau and remaining disease. During chemotherapy the calculated half-life is about 7.6 days, close to expected, and hCG has already normalized. The close explains that the run detects remaining disease and response but cannot tell scar from teratoma in the node.
PA 512 Week 7 rubric: what full points look like
Values written up without dates are the heaviest loss, since a brief about movement over time that cannot be placed in time has lost its subject. Comparing figures from different platforms as one run costs nearly as much and is easy to miss when results come from two laboratories. A movement inside the assay's own variation read as a real change is a further deduction, as is a pace claimed without the calculation behind it. Smaller losses come from a brief that runs long, from a run with no stated purpose and from conclusions the marker cannot support, such as the nature of a residual mass. The best briefs date every value, keep one assay, weigh movement against variation, calculate pace against a cited half-life, state what the run is for and what it cannot show.
PA 512 Week 7 help: mistakes that cost points
Marker briefs are short, which leaves no room for a value without a date or a comparison across assays. Starting from the run your section supplied, we can list each value with date and assay, set aside any that come from a different platform and check each movement against the stated variation. Working out an implied half-life from two dated values is arithmetic many students avoid, and seeing it once makes the pattern clear. We can also help you say plainly what the run is for and where its usefulness stops. The interpretation is yours. If your run is completely flat, the custom sample explains what a flat run does and does not tell the reader, which is still a finding.
Get a PA-512 Week 7 example written to your instructions
Send the values your section supplied with their dates, the assay or laboratory if it is given, and any length cap the assignment sets, and a custom example is written to them and returned inside 24 to 48 hours, the first one free. Where the run comes with a treatment timeline, include it, since the brief is read against that timeline.
More PA 512 papers and MPAS samples
- PA 512 Week 1: One Lab Figure Post
- PA 512 Week 2: CBC Interpretation Write-Up
- PA 512 Week 3: Peripheral Smear Correlation
- PA 512 Week 4: Anemia Indices Worksheet
- PA 512 Week 5: Serial Value Table
- PA 512 Week 6: TNM Staging Worksheet
- PA 512 Week 8: Treatment Response Summary
- PA 510 Week 7: Biopsy Site Justification
- PA 505 Week 7: Risk Formulation Note
- PA 504 Week 7: Note Revision Exercise
- PA 503 Week 7: Verbal Case Summary
PA 512 Week 7 questions, answered
How many values does a monitoring brief need?
Three or four is typical and the assignment usually supplies them. A pair gives a direction with no pace behind it, so briefs built on two values spend a line saying what a third would have added. If your section supplies a longer run, the brief still stays short and selects the values carrying the argument.
Does the brief state a diagnosis?
No, and most rubrics carry a row for exactly that boundary. The patient in these assignments is already known to the scenario, and the figures are being followed rather than used to open a question. A brief reaching for a diagnosis out of the run has left the genre it was set, whatever else it does well.
Our run is completely flat. Is there anything to write?
A flat run is a finding, and briefs built on one are often the better documents, because they have to argue from stability rather than from movement. The reading says the values held, states that the stability is wider than the assay variation, and gives what would have counted as a change. Send the run and the example is built on it.
Where can I find a free PA 512 Week 7 sample paper?
This page holds a complete PA 512 Week 7 tumor marker brief following AFP and hCG for a testicular germ cell tumor, with half-life calculations.
How does the PA 512 Week 7 sample show a plateau after surgery?
AFP should have fallen to roughly 260 to 345 ng/mL in a week at its usual half-life, but it stayed at 640, an implied half-life of more than two months.